Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris

 

The general recommendations developed in this guideline are based on the Living Cochrane review (https://pubmed.ncbi.nlm.nih.gov/35603936/). With new evidence and new results becoming available, the guideline development group will consider these and decide if and when an update is necessary. This will also be the case for the recommendations for specific clinical and comorbid situations.

 

 

Download entire guideline document in the 2021 version: 

 

Please note: The entire guideline document was last updated in 2021 and does not contain the latest information on the individual chapters. Below you can find the individual chapters that have been successively updated in the meantime. They will be incorporated into the entire guideline document when the updating process is completed.

Download
3736

Last updated
Changes
Download
Introduction, scoping, population and targeted users
10/2021
We welcome Ivan Bogdanov, Liam Mercieca and Dimitris Rigopoulos to the group.
Download
334
Disease severity and treatment goals
10/2021
No changes
Download
561
Methods and evidence section
12/2021
Editorial changes
Download
173
Main Recommendations and Decision Grid
10/2021
Bimekuzumab was added; guselkumab and PsA was added.
Download
673
Implementation slides
10/2021
Bimekuzumab was added; guselkumab and PsA was added
Download
303
IFPA Guideline
10/2021
No changes
Download
282

Last updated
Changes
Download
Acitretin
03/2023
No changes
Download
206
Ciclosporin
03/2023
Reference added
Download
161
Fumarates
03/2023
No changes
Download
93
Methotrexate
03/2023
New data added
Download
286
Adalimumab
03/2023
No changes
Download
140
Apremilast
03/2023
New data added
Download
162
Bimekizumab
10/2021
New chapter
Download
102
Brodalumab
10/2021
Section on IBD updated
Download
76
Certolizumab – Pegol
10/2021
No changes
Download
88
Etanercept
03/2023
No changes
Download
50
Guselkumab
03/2023
No changes
Download
107
Infliximab
03/2023
No changes
Download
56
Ixekizumab
10/2021
No changes
Download
93
Risankizumab
10/2021
No changes
Download
129
Secukinumab
10/2021
No changes
Download
103
Tildrakizumab
03/2023
No changes
Download
84
Ustekinumab
03/2023
No changes
Download
76
Biosimilars
10/2021
No changes
Download
61
Newly approved medications and treatments in the pipeline
10/2021
No changes
Download
150

Last updated
Changes
Download
Psoriatic arthritis
03/2023
New data added, recommendations changed
Download
205
Inflammatory bowel disease
10/2021
Recommendation concerning bimekizumab added
Download
81
Cancer
10/2021
Editorial changes
Download
185
Depression
10/2021
No changes
Download
63
Diabetes Mellitus
10/2021
No changes
Download
119
Heart disease
03/2023
New data added
Download
90
Kidney disease
03/2023
New data added
Download
52
Neurological diseases
10/2021
New data on ixekizumab added
Download
58
Viral Hepatitis
10/2021
No / update in progress
Download
150
Tuberculosis: Screening
10/2021
Editorial changes
Download
87
Tuberculosis: Treatment
10/2021
Editorial changes
Download
103
Wish for child / Pregnancy
10/2021
Time until pregnancy added for bimekizumab
Download
184
Vaccinations
03/2023
Completely new written
Download
130
Inmunogenicity
10/2021
No changes
Download
59

Last updated
Changes
Download
Methods Report
10/2021
No changes
Download
147
Strength and limitations
10/2021
No changes
Download
58
References
10/2021
Added new references
Download
58
Abbreviations
10/2021
No changes
Download
24